Schrag ML[au] - Search Results

Year	Number of Results
1988	1
2000	2
2001	3
2002	1
2003	2
2004	3
2005	1
2008	2
2009	1
2010	1
2022	0

1

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Harmange JC, Weiss MM, Germain J, Polverino AJ, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, DiPietro L, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Martin MW, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Wang L, White RD, Whittington DA, Zanon R. Harmange JC, et al. Among authors: schrag ml. J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7. J Med Chem. 2008. PMID: 18324761

2

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R. Weiss MM, et al. Among authors: schrag ml. J Med Chem. 2008 Mar 27;51(6):1668-80. doi: 10.1021/jm701098w. Epub 2008 Mar 7. J Med Chem. 2008. PMID: 18324759

3

Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.

Schrag ML, Wienkers LC. Schrag ML, et al. Arch Biochem Biophys. 2001 Jul 1;391(1):49-55. doi: 10.1006/abbi.2001.2401. Arch Biochem Biophys. 2001. PMID: 11414684

4

Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol.

Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD. Schrag ML, et al. Drug Metab Dispos. 2004 Nov;32(11):1299-303. doi: 10.1124/dmd.32.11.. Drug Metab Dispos. 2004. PMID: 15483196

5

Bacterial N-succinyl-L-diaminopimelic acid desuccinylase. Purification, partial characterization, and substrate specificity.

Lin YK, Myhrman R, Schrag ML, Gelb MH. Lin YK, et al. Among authors: schrag ml. J Biol Chem. 1988 Feb 5;263(4):1622-7. J Biol Chem. 1988. PMID: 3276674 Free article.

6

Heterotropic modulation of sulfotransferase 2A1 activity by celecoxib: product ratio switching of ethynylestradiol sulfation.

Cui D, Booth-Genthe CL, Carlini E, Carr B, Schrag ML. Cui D, et al. Among authors: schrag ml. Drug Metab Dispos. 2004 Nov;32(11):1260-4. doi: 10.1124/dmd.32.11.. Drug Metab Dispos. 2004. PMID: 15483193

7

Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.

Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Lu P, et al. Among authors: schrag ml. Drug Metab Dispos. 2003 Nov;31(11):1352-60. doi: 10.1124/dmd.31.11.1352. Drug Metab Dispos. 2003. PMID: 14570767

8

Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro.

Ma B, Shou M, Schrag ML. Ma B, et al. Among authors: schrag ml. Drug Metab Dispos. 2003 Nov;31(11):1300-5. doi: 10.1124/dmd.31.11.1300. Drug Metab Dispos. 2003. PMID: 14570759

9

Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans.

Atack JR, Wong DF, Fryer TD, Ryan C, Sanabria S, Zhou Y, Dannals RF, Eng WS, Gibson RE, Burns HD, Vega JM, Vessy L, Scott-Stevens P, Beech JS, Baron JC, Sohal B, Schrag ML, Aigbirhio FI, McKernan RM, Hargreaves RJ. Atack JR, et al. Among authors: schrag ml. J Pharmacol Exp Ther. 2010 Jan;332(1):17-25. doi: 10.1124/jpet.109.157909. Epub 2009 Sep 24. J Pharmacol Exp Ther. 2010. PMID: 19779131

10

Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.

Ma B, Subramanian R, Schrag ML, Rodrigues AD, Tang C. Ma B, et al. Among authors: schrag ml. Drug Metab Dispos. 2004 May;32(5):473-8. doi: 10.1124/dmd.32.5.473. Drug Metab Dispos. 2004. PMID: 15100167

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results